<DOC>
	<DOCNO>NCT00876031</DOCNO>
	<brief_summary>The purpose study investigate whether addition oral maintenance chemotherapy O-TIE ( Etoposide , Idarubicin , Trofosfamide ) 6 month improve event free survival ( EFS ) patient localise high-risk RMS RMS-like Soft Tissue Sarcoma .</brief_summary>
	<brief_title>Trial Localised High-risk Rhabdomyosarcoma Rhabdomyosarcoma-like Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Trofosfamide</mesh_term>
	<criteria>write informed consent registration , randomisation , data collection/transfer , tumour material asservation available pathologically ( include molecular pathology ) proven diagnosis rhabdomyosarcoma ( RMS ) RMSlike soft tissue sarcoma ( STS ) tumour material available pathology review Rhabdomyosarcoma `` High Risk '' Group , i.e . : RME , N0 , M0 , IRS II &amp; III , &gt; 5 cm &gt; 10 year EXT , HNPM , OTH , UGBP RME , N1 , M0 , IRSgroup , size age RMA , NO , M0 , IRSgroup , size age ( exception : paratesticular RMA eligible ) Rhabdomyosarcoma `` Very High Risk '' Group , i.e . : RMA , N1 , MO , IRS II &amp; III , size age localise highrisk RMSlike Soft Tissue Sarcoma , i.e . : EES , pPNET , UDS : N , M0 , IRSgroup , size age SySa , N , M0 , size age ( exception : SySa IRSI &amp; II , T2b , N0 , M0 eligible ) preexist illness prevent treatment ( esp . list medicinal product information , e.g . cardiac , hepatic , metabolic , renal dysfunction ; hypersensitivity ) previous malignant tumour available long term follow treat centre remission ( accord CWS2007HR definition ( see X7.1.8X ) ) time randomisation standard multimodal therapy e.g . accord CWSguidance pregnant lactate woman medical condition preclude treatment protocol therapy ( e.g . HIV , psychiatric disorder , etc . ) sexually active female male Arm B ( OTIE treatment ) : refusal use effective contraception ( e.g . oral , IUD )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pediatric soft tissue sarcoma</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>extraosseous Ewing family tumour</keyword>
	<keyword>synovial sarcoma</keyword>
	<keyword>undifferentiated sarcoma</keyword>
</DOC>